ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO531

Effectiveness of 12 Week Elbasvir/Grazoprevir (EBR/GZR) in Patients with Genotype 1 (GT1) Chronic Hepatitis C (HCV) and CKD

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 304 CKD: Epidemiology, Outcomes - Non-Cardiovascular


  • Nwankwo, Chizoba, Merck & Co, Lebanon, New Jersey, United States
  • Bacon, Bruce R., Saint Louis University School of Medicine, Saint Louis, Missouri, United States
  • Curry, Michael P., Beth Israel Deaconess Medical Center, Boston, Alabama, United States
  • Flamm, Steven, Northwestern Feinberg School of Medicine, Chicago, Illinois, United States
  • Kowdley, Kris V, Swedish Medical Center, Seattle, Washington, United States
  • Milligan, Scott, Trio Health Analytics, La Jolla, California, United States
  • Tsai, Naoky, University of Hawaii, Kailua, Hawaii, United States

Elbasvir/grazoprevir (EBR/GZR) is recommended for use in the treatment of chronic HCV genotype (GT) 1 and 4 patients including those with renal impairment. The puprose of this study is to describe the real-world effectiveness of 12 week EBR/GZR in patients with GT1 chronic HCV and CKD.


Data were collected from US providers and specialty pharmacies through Trio Health’s disease management platform. Patients with CKD and GT1 HCV who initiated 12 week EBR/GZR therapy between Jan 28, 2016 (FDA approval) to Dec 31, 2016 were included in the analyses. CKD was defined as renal impairment of baseline eGFR <90 ml/min. Effectiveness was defined as attainment of per protocol sustained virological response at week 12 post-treatment (PP SVR12).


228 patients with GT1 HCV and CKD were treated for 12 weeks with EBR/GZR and ribavirin (RBV) was added for 6 patients. 25% (56/228) of patients had mild stage 2 CKD, 21% (48/228) had moderate stage 3 CKD and 54% (124/228) had severe renal impairment (CKD stages 4-5). Other characteristics provided in (TABLE). At time of abstract submission, 144 of 228 were evaluable for PP SVR12; 98% (135/138) of patients treated with EBR/GZR and 100% (6/6) of patients treated with EBR/GZR+RBV achieved PP SVR12.


In the treatment of patients with GT1 chronic HCV and CKD, 12 week EBR/GZR was highly effective with an overall SVR12 (PP) of 98% (141/144).


  • Commercial Support